The pharmaceutical sector is actively working to develop and commercialize 5-MeO-DMT, a potent psychedelic compound also known as BUFO, aiming to establish it as a novel treatment for serious mental health disorders. Companies such as AtaiBeckley and GH Research are directing significant resources towards clinical trials and regulatory approval processes. Their goal is to transition 5-MeO-DMT from its current use in informal clinics, particularly in Mexico, into a recognized and regulated therapeutic option for conditions like depression, anxiety, and PTSD.
This emerging market has the potential to become a multi-billion-dollar segment within the biotech industry. The Wall Street Journal highlights the ongoing efforts and investments driving this transition, emphasizing the commercial and medical promise of 5-MeO-DMT. As the drug moves through development stages, it represents a significant shift towards expanding psychedelic therapies beyond traditional frameworks and into mainstream medical practice.